Wegener's Granulomatosis Clinical Trial
Official title:
An Open Label Pilot Study Examining the Use of Rituximab in Patients With Wegener's Granulomatosis Who Have Experienced Disease Relapse on Standard Therapies
This study will examine the use of rituximab in patients with Wegener's granulomatosis (WG)
who have experienced a relapse of the disease through standard therapies. Rituximab is an
antibody directed against the human protein called CD20, found on the surface of normal and
abnormal B lymphocytes. Rituximab decreases the number of B lymphocytes. This study will
examine the safety of rituximab in WG and rituximab's ability to reduce the level of
circulating antineutrophil cytoplasmic antibodies (ANCA), which are antibodies that react to
substances found in white blood cells. ANCA have been found to be strongly associated with
WG. The study will also explore whether rituximab can reduce the occurrence of disease
relapse. WG is a disease marked by inflammation of blood vessels. It can involve many
different parts of the body, including the sinuses, lungs, kidneys, brain, nerves, eyes,
intestinal tract, skin, joint, heart, and others. Before the use of cytotoxic drug therapy,
WG was almost always fatal if untreated, with a mortality rate of 93% within 2 years.
Patients 18 to 75 years of age who have a history of at least one relapse of the disease
despite standard treatments, who have had active WG within the previous 12 months and are in
remission, who are receiving either methotrexate or azathioprine for remission maintenance,
and who have circulating ANCA, may be eligible for this study.
A minimum of 22 visits to the clinic will be required to complete the entire study. Patients
will undergo a comprehensive medical evaluation, with laboratory studies and x-rays. There
may also be consultations and possible biopsies of affected organs only if medically
indicated for diagnosis and treatment of the disease. In the 4-week period that patients
will receive rituximab infusions, the methotrexate or azathioprine will be continued at the
same dosage unless there are side effects that requite the medication to be temporarily
stopped or the dosage reduced. Patients will receive four doses of rituximab, at 375 mg per
meter squared of body surface area, once a week. It will be infused into a vein, through an
intravenous catheter. For the first dose, patients will be admitted as inpatients for at
least 24 hours, for monitoring during the infusion and for any reactions associated with it.
The second, third, and fourth rituximab infusions may be given either on an inpatient or
outpatient basis to be decided on how the patient tolerates the first infusion.
Following the four infusions, there will be blood tests to monitor the safety of the
medication and the status of the disease, to be done at home every week for 4 weeks. Results
will be sent to the researchers by fax. Patients will be asked to return to the clinic 1
month after the fourth infusion and every 1 to 3 months afterward. If there are no side
effects or a relapse of the disease, the methotrexate or azathioprine will be continued for
2 years past remission. If by then the disease then remains in remission, the dose of either
medication will be gradually decreased and eventually stopped. The usual schedule is to
reduce methotrexate by 2.5 mg per month and to reduce azathioprine by 25 mg per month. If at
that point there are no signs of active disease, the patients' illness will be considered to
be in continued remission and no further treatment will be necessary. If relapse does occur,
treatment would be different than previously. In most cases, treatment would involve
prednisone and cyclophosphamide or methotrexate If the ANCA finding is negative after
rituximab treatment and again becomes positive, and there is evidence of a return of B
lymphocytes, patients may receive a second course of four rituximab infusions.
This pilot study will seek to investigate the use of rituximab in patients with Wegener's granulomatosis who have experienced disease relapse through standard therapies. Rituximab is a chimeric monoclonal antibody directed against CD20, which induces B cell death and results in rapid and sustained depletion of circulating and tissue-based B cells. The objectives of this protocol will be to establish the safety of rituximab in Wegener's granulomatosis, to examine the ability of rituximab to reduce the level of circulating antineutrophil cytoplasmic antibodies (ANCA), and to preliminarily explore whether rituximab is able to prevent disease relapse. This prospective standardized open label trial will enroll 10 patients who have a well-documented history of disease relapse while receiving immunosuppressive therapy given according to published regimens and who are ANCA positive after remission induction. Patients will be enrolled once they have achieved remission from a recent relapse and are receiving either methotrexate or azathioprine for remission maintenance. All patients will receive rituximab 375 mg/M(2) once a week for 4 weeks. During and following the rituximab treatment period, patients will remain on their remission maintenance agent of methotrexate or azathioprine. Patients who are enrolled while on prednisone will continue to taper the dosage to discontinuation as medically permitted. Following the 4 weekly infusions of rituximab, patients will be followed prospectively for evidence of effective B cell depletion, features of drug toxicity, level of circulating ANCA, and clinical disease status. Patients whose ANCA levels become undetectable following the infusion of rituximab may be retreated with a second 4 week course of rituximab should their ANCA titer become positive (greater than or equal to 1:40) and there has been a return of B cells in the peripheral blood. Methotrexate or azathioprine will be continued for two years past remission, after which time, this will be tapered and discontinued. Patients will continue to be monitored for two years off all immunosuppressive therapy or if a disease relapse should occur, for a minimum of 12 months after the last rituximab infusion. ;
Endpoint Classification: Safety Study, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT00747461 -
Interventional Cryotherapy for the Eradication of Benign Airway Disease ("ICE the BAD")
|
Phase 4 | |
Recruiting |
NCT02593565 -
Vasculitis Pregnancy Registry
|
||
Completed |
NCT01167491 -
Study of One Protein Implicated in Wegener Disease
|
N/A | |
Completed |
NCT00307593 -
RATTRAP: Infliximab Versus Rituximab in Systemic Necrotizing Vasculitides
|
N/A | |
Active, not recruiting |
NCT00006055 -
Autologous Peripheral Blood Stem Cell Transplantation in Patients With Life Threatening Autoimmune Diseases
|
N/A | |
Terminated |
NCT01408836 -
Plasma Exchange for Renal Vasculitis
|
Phase 2/Phase 3 | |
Completed |
NCT00001473 -
Cyclophosphamide and Prednisone Followed by Methotrexate To Treat Vasculitides
|
N/A | |
Completed |
NCT00001256 -
Steroids and Methotrexate to Treat Systemic Vasculitis
|
Phase 2 | |
Completed |
NCT00040248 -
Daclizumab to Treat Wegener's Granulomatosis
|
Phase 2 | |
Completed |
NCT00005007 -
Etanercept for Wegener's Granulomatosis
|
Phase 2/Phase 3 | |
Completed |
NCT00307671 -
Treatment of Necrotizing Vasculitides for Patients Older Than 65 Years
|
Phase 4 | |
Completed |
NCT01988506 -
Induction of Regulatory t Cells by Low Dose il2 in Autoimmune and Inflammatory Diseases
|
Phase 2 | |
Recruiting |
NCT01066208 -
American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) Diagnostic and Classification Criteria for Primary Systemic Vasculitis
|
N/A | |
Completed |
NCT00104299 -
Rituximab for the Treatment of Wegener's Granulomatosis and Microscopic Polyangiitis
|
Phase 2/Phase 3 | |
Completed |
NCT00753103 -
Anti-Cytokine Therapy for Vasculitis
|
Phase 2 | |
Completed |
NCT02176070 -
Reproductive Health in Men and Women With Vasculitis
|
N/A | |
Completed |
NCT00468208 -
Abatacept in Treating Adults With Mild Relapsing Wegener's Granulomatosis
|
Phase 1/Phase 2 | |
Completed |
NCT00004567 -
Comparison of Treatments to Maintain Disease Remission in Patients With Wegener's Granulomatosis and Related Vasculitis Syndromes
|
Phase 2 | |
Completed |
NCT00001901 -
Etanercept to Treat Wegener's Granulomatosis
|
Phase 2 | |
Completed |
NCT00430105 -
Pulse Versus Continuous Cyclophosphamide for Induction of Remission in ANCA-Associated Vasculitides
|
Phase 2/Phase 3 |